The use of subcutaneous injections to deliver Velcade treatment is comparable in activity, but associated with fewer side effects, than the standard delivery of IV injections in multiple myeloma patients.

“We have similar efficacy with subcutaneous [injections] and a more convenient route of administration for patients, especially those with poor venous access. We don’t require IV central lines, and we do have, most importantly, a reduction in toxicities, which, in my opinion, is really important for our patients,” said Dr. Philippe Moreau, the lead investigator of the University Hospital in Nantes, France, …